Skip to main content

Advertisement

SpringerLink
Log in

A role for leukemia inhibitory factor in melanoma-induced bone metastasis

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Melanoma is commonly associated with multi-organ metastasis, and bone is a frequent metastatic site for melanoma. However, the mechanism responsible for such melanoma-induced bone metastasis is still poorly understood. In the present study, the intracardiac inoculation of leukemia inhibitory factor (LIF)-producing human melanoma-derived cells (SEKI) developed osteolytic bone destruction in male BALB/cA-nu/nu nude mice. To elucidate the role of LIF in melanoma-induced osteolysis, cells were prepared in which the expression of LIF was reduced using a siRNA technique from the parent SEKI cells. Osteoclastogenesis was induced in the co-culture of LIF and/or SEKI cells with osteoblastic stromal cells in vitro, whereas the LIF-reduced SEKI cells did not induce osteoclastogenesis. The intracardiac inoculation of LIF-reduced SEKI cells resulted in a significant reduction in the incidence and number of bone metastasis in comparison to those in the mice inoculated with the parent SEKI cells. The expression of LIF was found in seven of nine human melanoma-derived cell lines, suggesting that LIF expression is a universal event in melanoma. These findings suggest that a potential role for LIF in the melanoma-induced bone metastasis possibly through the stimulation of osteoclastogenesis. LIF might therefore be a potentially effective drug target in the treatment of bone metastasis in melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

LIF:

Leukemia inhibitory factor

PTHrP:

Parathyroid hormone-related protein

GAPDH:

Glyceraldehydes-3-phosphate dehydrogenase

siRNA:

Small interfering RNA

TRAP:

Tartrate-resistant acid phosphatase

DAB:

3,3′-Diaminobenzidine tetrahydrochloride

HPCs:

Hematopoietic cells

OCLs:

Osteoclasts

BV:

Bone volume

TV:

Tissue volume

ES:

Eroded bone surface

BS:

Bone surface

References

  1. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664. doi:10.1056/NEJMra030831

    Article  PubMed  CAS  Google Scholar 

  2. Iguchi H, Tanaka S, Ozawa Y et al (1996) An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 56:4040–4043

    PubMed  CAS  Google Scholar 

  3. Croucher PI, Shipman CM, Lippitt J et al (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534–3540. doi:10.1182/blood.V98.13.3534

    Article  PubMed  CAS  Google Scholar 

  4. Abe M, Hiura K, Wilde J et al (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195–2202

    PubMed  CAS  Google Scholar 

  5. Guise TA, Yin JJ, Taylor SD et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544–1549. doi:10.1172/JCI118947

    Article  PubMed  CAS  Google Scholar 

  6. Onuma E, Sato K, Saito H et al (2004) Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res 24:2665–2673

    PubMed  CAS  Google Scholar 

  7. Shimoyama M (1975) SEKI strain. In: Oboshi S, Sugano H (eds) In vitro culture of human cancer cells. Asakura Shoten, Tokyo, pp 208–215

    Google Scholar 

  8. Kondo Y, Sato K, Ueyama Y et al (1981) Serum sialyltransferase and liver catalase activity in cachectic nude mice bearing a human malignant melanoma. Cancer Res 41:2912–2916

    PubMed  CAS  Google Scholar 

  9. Mori M, Yamaguchi K, Honda S et al (1991) Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51:6656–6659

    PubMed  CAS  Google Scholar 

  10. Gearing DP, Gough NM, King JA et al (1987) Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 6:3995–4002

    PubMed  CAS  Google Scholar 

  11. Kurzrock R, Estrov Z, Wetzler M et al (1991) LIF: not just a leukemia inhibitory factor. Endocr Rev 12:208–217

    Article  PubMed  CAS  Google Scholar 

  12. Alexander HR, Billingsley KG, Block MI et al (1994) D-factor/leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine 6:589–596. doi:10.1016/1043-4666(94)90045-0

    Article  PubMed  CAS  Google Scholar 

  13. Palmqvist P, Persson E, Conaway HH et al (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169:3353–3362

    PubMed  CAS  Google Scholar 

  14. Takahashi N, Akatsu T, Udagawa N et al (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600–2602

    Article  PubMed  CAS  Google Scholar 

  15. van de Wijngaert FP, Burger EH (1986) Demonstration of tartrate-resistant acid phosphatase in un-decalcified, glycolmethacrylate-embedded mouse bone: a possible marker for (pre)osteoclast identification. J Histochem Cytochem 34:1317–1323

    PubMed  Google Scholar 

  16. Arguello F, Furlanetto RW, Baggs RB et al (1992) Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/Sld and W/Wv). Cancer Res 52:2304–2309

    PubMed  CAS  Google Scholar 

  17. Oda Y, Takahira T, Kawaguchi K et al (2003) Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 34:1035–1042. doi:10.1053/S0046-8177(03)00404-0

    Article  PubMed  CAS  Google Scholar 

  18. Bendre MS, Gaddy-Kurten D, Mon-Foote T et al (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571–5579

    PubMed  CAS  Google Scholar 

  19. Bendre MS, Margulies AG, Walser B et al (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65:11001–11009. doi:10.1158/0008-5472.CAN-05-2630

    Article  PubMed  CAS  Google Scholar 

  20. Ono K, Akatsu T, Murakami T et al (2002) Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17:774–781. doi:10.1359/jbmr.2002.17.5.774

    Article  PubMed  CAS  Google Scholar 

  21. Mattei S, Colombo MP, Melani C et al (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853–857. doi:10.1002/ijc.2910560617

    Article  PubMed  CAS  Google Scholar 

  22. Sanchez-Sweatman OH, Lee J, Orr FW et al (1997) Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 33:918–925. doi:10.1016/S0959-8049(97)00513-3

    Article  PubMed  CAS  Google Scholar 

  23. Wysoczynski M, Miekus K, Jankowski K et al (2007) Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas. Cancer Res 67:2131–2140. doi:10.1158/0008-5472.CAN-06-1021

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, 811-1395, Japan

    Shigeaki Maruta & Soichi Takiguchi

  2. Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, 814-0180, Japan

    Miho Ueyama & Yasufumi Kataoka

  3. Department of Anatomical Pathology, Graduate school of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan

    Yoshinao Oda & Masazumi Tsuneyoshi

  4. Clinical Research Institute, Shikoku Cancer Center, Minamiumemotomachi Ko160, Matsuyama, Ehime, 791-0280, Japan

    Haruo Iguchi

Authors
  1. Shigeaki Maruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soichi Takiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miho Ueyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasufumi Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinao Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masazumi Tsuneyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haruo Iguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haruo Iguchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maruta, S., Takiguchi, S., Ueyama, M. et al. A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clin Exp Metastasis 26, 133–141 (2009). https://doi.org/10.1007/s10585-008-9223-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-008-9223-x

Keywords

Search

Navigation